| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

National Centers for Immunization and Respiratory Diseases, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Branch,1 Division of Viral and Rickettsial Diseases, Special Pathogens Branch,2 Poxvirus Activity,3 Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE, Atlanta, Georgia,4 AlphaVax, Inc., Research Triangle Park, North Carolina,5 Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, Massachusetts,6 National Institute of Hygiene and Epidemiology, Hanoi, Vietnam7
Received 26 September 2006/ Returned for modification 31 October 2006/ Accepted 8 January 2007
Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.
Published ahead of print on 17 January 2007.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |